Abstract
INO-1001 is a PARP-1 inhibitor that interrupts the repair process of N-methylpurines generated by temozolomide. We evaluated the pharmacokinetics of INO-1001 and determined its safety when used with temozolomide at 200 mg/m2/day x 5 days every 4 weeks. We enrolled 12 adult patients, in cohorts of 3-6 patients, into the study. INO-1001 at doses of 100, 200 and 400 mg was given intravenous for 1 hr q 12 hr for 10 doses. INO-1001 had a moderate clearance, volume of distribution and a relatively short terminal half-life. Myelosuppression and elevation of liver transaminases were dose-limiting toxicities (DLTs) of INO-1001 at 400 mg.
Original language | English (US) |
---|---|
Pages (from-to) | 756-763 |
Number of pages | 8 |
Journal | Cancer Investigation |
Volume | 27 |
Issue number | 7 |
DOIs | |
State | Published - Aug 2009 |
Keywords
- INO-1001
- Melanoma
- PARP inhibitor
- Pharmacokinetics
- Temozolomide
ASJC Scopus subject areas
- Oncology
- Cancer Research
MD Anderson CCSG core facilities
- Clinical and Translational Research Center
- Clinical Trials Office